FHI Clinical Inc. Providing Services for ACTT-1 Trial of Remdesivir for COVID-19 Treatment
FHI Clinical Inc. has announced that it has a subcontract with the Frederick National Laboratory for Cancer Research to provide clinical operations services for the Adaptive COVID-19 Treatment Trial (ACTT), a study to allow investigation of putative therapeutics, for the treatment of COVID-19 in hospitalized adults. The first iteration, from ACTT-1, included 1,063 participants recruited within an eight-week period at 60 study sites and 13 subsites from places like in Denmark, Germany, Japan, Korea, Singapore, the United States, and more. ACTT-2 is now open.
For more information, click here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
